Y Combinator

Y Combinator-backed start-up, focused on non-AAV, non-LNP delivery of genetic material, announces first pharma partnership

Plus: Big rounds for Element, Beacon and Myricx

Plus: Astellas drops IRA lawsuit after CMS passes on Xtandi and updates on Ultomiris, Rybrevant, exo-cel, Tentarix, Rejuvenation, and more

Plus: Co-founded by Slamon, ADC play Torl debuts with $158M B round and updates from Lux, Wellington, Lilly, Novo and more   

Plus: F-star takeout remains in CFIUS limbo and updates from Seagen, Astellas, Merck, Catalyst, Eisai and more

Plus Autobahn heads for treatment-resistant depression with $32M round and updates on Amylyx, Reata, Integral Molecular and more 

Plus: Setback for Myovant at FDA and updates from Takeda, Ocugen, Prilenia, AbbVie and more

Plus Apple Tree funds Crick Institute spinout, METiS launches, Flagship, Persephone and more

Plus: Travecta, MTS Health Partners, Elevar and Y Combinator

Emerging Company Profile: Asher Bio engineering cytokine specificity with Third Rock-led $55 million series A